Denmark's Curasight Q1 net loss widens
Denmark's Curasight Q1 net loss widens
Overview
Denmark radiopharmaceutical developer's Q1 net loss widened from a year earlier
Company reported preliminary positive data from Phase 1 uTREAT trial in high-grade gliomas
Curasight increased international visibility via participation in major healthcare conferences
Outlook
Company says it remains focused on clinical execution and milestone delivery during 2026
Result Drivers
Co said it continued progress on uTREAT and uTRACE platforms, advancing its theranostic strategy targeting uPAR
PHASE 1 TRIAL DATA - Co announced encouraging preliminary data from ongoing Phase 1 trial of uTREAT in high-grade gliomas
Company press release: ID:nWkr3TMQqQ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 EPS |
| -DKK 0.32 |
|
Q1 Net Income |
| -DKK 15.33 mln |
|
Q1 Operating Income |
| -DKK 15.28 mln |
|
Q1 Pretax Profit |
| -DKK 16.70 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Curasight A/S is DKK8.00, about 48.9% below its May 27 closing price of DKK15.65
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)